Testicular changes after treatment with a GnRH analog (buserelin) in association with cyproterone acetate in men with prostatic cancer.
Twelve patients (age range: 53-78 years) with prostatic cancer were treated with Buserelin (1.2 mg/day) and cyproterone acetate (150 mg/day). Testicular biopsies performed after 13-96 weeks of treatment were compared to those obtained from 6 untreated men of similar age. Deranged spermatogenesis was observed in all but 1 treated patient. The appearance of immature Sertoli cells and atrophic Leydig cells suggests a condition of pharmacologic 'hypophysectomy'. The variable damage to the seminiferous epithelium and findings of an incomplete involution of Leydig cells suggested a decreased but still present testicular steroidogenesis.
Properzi
G
G
Department of Internal Medicine (Andrology), University of L'Aquila, Italy.
Francavilla
S
S
Vicentini
C
C
Cordeschi
G
G
Galassi
P
P
Paradiso Galatioto
G
G
Miano
L
L
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D002064:Buserelin / Q000008:administration & dosage; D003534:Cyproterone / Q000008:administration & dosage / Q000031:analogs & derivatives; D017373:Cyproterone Acetate; D004359:Drug Therapy, Combination; D006801:Humans; D007985:Leydig Cells / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012708:Sertoli Cells / Q000187:drug effects; D013091:Spermatogenesis / Q000187:drug effects; D013733:Testicular Diseases / Q000139:chemically induced* / Q000473:pathology; D013739:Testosterone / Q000097:blood
D013739:Testosterone; D017373:Cyproterone Acetate; D003534:Cyproterone; D002064:Buserelin